About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Blogroll Update | Main | Roche: Layoffs, or Rumors? »

August 30, 2010

How About The Same Price You Turned Down Before? Hmm?

Email This Entry

Posted by Derek

Well, so much for my fantasy of Sanofi-Aventis walking away from their attempt to buy Genzyme. They went public yesterday with a $69/share offer - even lower than most people were thinking - and just a little while ago, Genzyme publicly turned them down.

What's more, this is apparently the same price at which Genzyme (privately) balked earlier in the summer. The big difference now, of course, is that the dollar figures are out in the newspapers. And the only reason to do it that way, at least as far as I can figure, is if you're going to try to wage a hearts-and-minds battle for Genzyme's shareholders: a hostile offer, or at least the credible threat of one.

I'm in no position to say how well that'll work out. Sanofi-Aventis has, presumably, been sounding out the larger institutional investors to see if they can get something going, while Genzyme has surely been telling them to stick with the current management for a better deal. The big issue is the uncertainty about when the company is going to get its manufacturing problems taken care of. No doubt that's going to be one of the selling points for a hostile bid: "Do you really want to stick with the people who let this happen? And do you really trust them to get it cleaned up when they say that they will?" But that same uncertainly clouds the pricing of the hostile offer itself. Thus. . .$69/share.

If I had to guess, I'd say that the two sides, after a lot of fist-waving, will reach some sort of face-saving figure in the mid-70s. Will the guy that sold all those October $75 calls make out or not?

Comments (0) + TrackBacks (0) | Category: Business and Markets


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry